SURGICAL HEMOSTATS, INTERNAL TISSUE SEALANTS, AND ADHESION BARRIERS MARKET ANALYSIS

Market Challenges And Opportunities

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market – Driver

Increasing prevalence of cardiovascular surgeries

The growing incidences of cardiovascular diseases are a major factor leading to the high demand for hemostats and tissue sealants. For instance, according to Heart Disease and Stroke Statistics 2022 published by the American Heart Association on February 22, 2022. In 2020, 3,658 heart transplants were performed in the United States. The highest numbers of heart transplantations were seen in California (496), Texas (302), Florida (288), and New York (250). Cardiac catheterization was the most common procedure for all years presented. An estimated 480,000 percutaneous transluminal coronary angioplasties, 371,000 inpatient bypass procedures, 1,016,000 inpatient diagnostic cardiac catheterization, 86,000 carotid endarterectomies, and 351,000 pacemaker procedures were performed for inpatients in the United States.

Introduction of products in market by key market players

The increasing launches of newer products in the market can drive the growth of the global surgical hemostats, internal tissue sealants, and adhesion barriers market. For instance, on February 23, 2022, Gunze Limited, a Japan-based medical device company, received medical device approval to manufacture and sell TENALEAF, the sheet-type absorbable adhesion barrier made in Japan. This product provides surgeons with a new option during open surgery and minimally invasive surgery, which can enable easy manipulation, and provide moderate adhesive strength for repositioning and conformable placement.

Restraint

High costs of procedures using surgical hemostats, internal tissue sealants, and adhesion barriers

The cost of treatment associated with surgical hemostats, internal tissue sealants, and adhesion barriers is very high. As it is an expensive method, this can restrain the growth of the market. According to an article published by the Journal of Vascular Surgery on June 2021, in order to prevent postoperative adhesions, patients need to undergo additional operations, which increases their medical costs and physical burden. Cost of agents varies depending on the ingredient used. Using an adhesion barrier in laparoscopic procedures increases costs by nearly US$ 162.

This restraint can be overcome by the introduction of newer government reimbursement policies that can help patients financially.

Costly research and development activities of surgical hemostats, internal tissue sealants, and adhesion barriers

The research and development activities for surgical hemostat and tissue sealant are very costly. This can affect the growth of the global surgical hemostats, internal tissue sealants, and adhesion barriers market. For instance, according to an article published by The Journal Gels on January 23, 2023, the high cost of research development are also related to high cost of the raw materials used for preparation of polymers. The time required for the R&D process is also 8-10 years which is included in the final cost. Hemostatic agents with oxidized regenerated cellulose, absorbable matrix, or microporous polysaccharide constituents are least expensive agents US$ 50-US$ 100. Agents made with microfibrillar collagen costs nearly US$ 100-US$ 300. Biologically active agents, made with virus-inactivated human fibrinogen and human thrombin are priced US$ 301-US$ 500. Dual agents containing both thrombin and absorbable gelatin, have prices between US$ 301 and US$ 500. Of all agents, synthetic adhesives were the most expensive >US$ 500.

This can be overcome introduction of newer methods to synthesize the polymers in cost-effective manner.